Alliance E-News - February 2026
Spotlight on Alliance Leadership
 

Alliance Appoints New Alliance Lymphoma Committee Co-Chairs









The Alliance for Clinical Trials in Oncology has appointed two new Co-Chairs of the Alliance Lymphoma Committee: Ann S. LaCasce, MD, MMSc, and Jeremy S. Abramson, MD, MMSc. Drs. LaCasce and Abramson assumed these leadership roles on February 1, 2026, succeeding John P. Leonard, MD, whose distinguished and longstanding leadership have been instrumental in advancing the Alliance’s lymphoma research portfolio. As he steps down from his role, Dr. Leonard expressed his deep appreciation to Nancy L. Bartlett, MD, Vice Chair of the Alliance Lymphoma Committee, for her exceptional contributions, leadership, and collaborative partnership. Dr. Leonard was recently named Chief of the Division of Hematology & Medical Oncology and Director of the Center for Blood Cancers at NYU Langone Health.

Ann S. LaCasce, MD, MMSc
Dr. LaCasce is a nationally recognized leader in lymphoma research and patient care. She is an Associate Professor of Medicine at Harvard Medical School, Director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology, and a senior physician at Dana-Farber Cancer Institute, where she specializes in the treatment of both Hodgkin and non-Hodgkin lymphomas. Dr. LaCasce has played a central role in the development and leadership of numerous multicenter clinical trials, with a particular focus on novel therapeutic approaches and improving outcomes for patients with relapsed and refractory disease. She is widely respected for her collaborative leadership style, mentorship of early-career investigators, and longstanding commitment to cooperative group research.

Jeremy S. Abramson, MD, MMSc
Dr. Abramson is a Professor of Medicine at Harvard Medical School and Director of the Jo Ann Hagler Center for Lymphoma at Massachusetts General Hospital. An internationally recognized expert in aggressive lymphomas and cellular therapies, Dr. Abramson has led and contributed to pivotal clinical trials evaluating CAR T-cell therapy and other immune-based treatments. His work has helped shape current standards of care for patients with high-risk and relapsed lymphoma. Dr. Abramson is known for his translational research efforts, bringing innovative therapies from the laboratory into clinical practice, as well as his strong engagement in collaborative clinical research networks.

Together, Drs. LaCasce and Abramson bring complementary expertise, a shared vision for innovation, and a deep commitment to the Alliance mission. Their leadership will guide the Alliance Lymphoma Committee as it continues to develop impactful clinical trials and improve outcomes for patients with lymphoma.

Alliance thanks Drs. Leonard and Bartlett for their exceptional service and welcomes Drs. LaCasce and Abramson to their new roles.

 

 

Read more articles in this issue: